Company Overview and News

 
ZBH / Zimmer Biomet Holdings, Inc null

2018-10-04 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C$Q,R P(&]B:@T\/"],:6YE87)I>F5D(#$O3" Q M,C W,3%LQ,3,@ M,C9=+TEN9F\@,3$R(# @4B],[email protected]@-S(O4')E=B Q,C S-C$O4F]O=" Q M,[email protected],"!2+U-I>[email protected],3,Y+U1Y<&4O6%)E9B][email protected],B Q73X^<;0( ! + @"A<-"F5N9'-T
ZBH

 
ZBH / Zimmer Biomet Holdings, Inc null

2018-10-04 sec.gov
zbh-corresp.htm
ZBH

 
ZBH / Zimmer Biomet Holdings, Inc null

2018-10-04 sec.gov
zbh-corresp.htm
ZBH

 
ZBH / Zimmer Biomet Holdings, Inc null

2018-10-04 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C0S(# @;V)J#3P\+TQI;F5A(2 (2['U XG,Z Q,CPRZ0+ ,C >(_XZR? $& .RT!NL- M"F5N9'-T
ZBH

2
ZBH / Zimmer Biomet Holdings, Inc FORM 8-K (Current Report)

2018-08-27 sec.gov - 2
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ZBH

 
ZBH / Zimmer Biomet Holdings, Inc 10-Q (Quarterly Report)

2018-08-06 sec.gov
zbh-10q_20180630.htm UNITED STATES
ZBH

 
ZBH / Zimmer Biomet Holdings, Inc FORM 8-K (Current Report)

2018-08-03 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
ZBH

8
Cramer's lightning round: The case for buying shares of UnitedHealth

2018-07-31 cnbc
Evolent Health: "It's a good platform but you know what? [When] I come back to that group, I always come back to [the idea] that you have to buy the best of breed that's large-cap in it, which I am going to say would be UnitedHealth. Now, you could say, wait a second, that doesn't have it, but if you look at Optum, then you will say it does. Buy some UnitedHealth."
DCP EVH IDXX WES ZBH TRTN

 
Zimmer Biomet Holdings, Inc. (ZBH) CEO Bryan Hanson on Q2 2018 Results - Earnings Call Transcript

2018-07-27 seekingalpha
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Q2 2018 Earnings Conference Call July 27, 2018 8:30 AM ET
ZBH

2
Zimmer Biomet (ZBH) Q2 Earnings Top Estimates, Margins Drop

2018-07-27 zacks
Zimmer Biomet Holdings, Inc. (ZBH - Free Report) reported second-quarter 2018 adjusted earnings per share of $1.92, down 7.7% year over year and ahead of the Zacks Consensus Estimate of $1.88.
RSG AMED ZBH PODD

1
Zimmer Biomet (ZBH) Beats on Q2 Earnings & Revenue Estimates

2018-07-27 zacks
Ever undergone reconstructive orthopedic surgery? Yes, then you may have been implanted with one of the personalized joint replacement technologies of Indiana-based, one of the leading orthopedic medical devices manufacturer–Zimmer Biomet Holdings, Inc. (ZBH - Free Report) , formerly known as Zimmer Holdings. In June 2015, legacy Zimmer completed the acquisition of Biomet for $14.0 billion. With operations in more than 25 countries, the company markets its orthopedic reconstructive, spinal and trauma devices, biologics, dental implants and related surgical products in more than 100 countries.
FSWB NVR ZBH TRN FSBW

 
ZBH / Zimmer Biomet Holdings, Inc 8-K (Current Report)

2018-07-27 sec.gov
zbh-8k_20180630.htm UNITED STATES
ZBH

5
What's in the Cards for Zimmer Biomet (ZBH) in Q2 Earnings?

2018-07-17 zacks
Zimmer Biomet Holdings, Inc. (ZBH - Free Report) is set to report second-quarter 2018 results on Jul 27, before the markets open.
ALGN BSX BAX ZBH

58
NuVasive's (NUVA) Global Prospects Solid, Competition Rife

2018-06-05 zacks
On Jun 4, we issued an updated research report on NuVasive, Inc. (NUVA - Free Report) . We are upbeat about the company’s flourishing international business, which holds immense opportunity. However, a highly competitive landscape is a concern for this Zacks Rank #3 (Hold) company.
BRK.A DB SYK NUVA ISRG ZBH

83
Medtronic: Wall Street’s Views and Latest Recommendations

2018-06-01 marketrealist
Medtronic (MDT) is the largest pure-play medical device company in the world. It offers products across four segments: CVG (Cardiac and Vascular Group), MITG (Minimally Invasive Therapies Group), RTG (Restorative Therapies Group), and DG (Diabetes Group). Since the company’s earnings release on May 24, MDT stock has fallen ~1.8%. Let’s see what Wall Street analysts are recommending for the stock.
ABT MS ZBH ABT

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: 98956P102